Conference Presentations, Settlement and License Agreement, New Leadership, and Start of Phase III Study - Analyst Notes on Alexion, Mylan, Novartis, GSK and Intercept

NEW YORK, June 11, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Mylan Inc (NASDAQ: MYL), Novartis AG (ADR) (NYSE: NVS), GlaxoSmithKline plc (ADR) (NYSE: GSK) and Intercept Pharmaceuticals Inc (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3594-100free.

--
Alexion Pharmaceuticals, Inc. Analyst Notes
On June 3, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced that its management will present at the Wells Fargo Securities 2014 Healthcare Conference on June 17, 2014, at 3:30 p.m. ET, in Boston, Massachusetts. According to the Company, a live audio webcast and an archived version of the presentation will available on Alexion's website. The archived version will be available for a limited time after the conference. The full analyst notes on Alexion are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/ALXN/report.pdf

--
Mylan Inc Analyst Notes
On June 2, 2014, Mylan Inc (Mylan) announced that it has entered into a settlement and license agreement with Pfizer Inc. regarding its Abbreviated New Drug Application (ANDA) filed with the U. S Food and Drug Administration (FDA) for Celecoxib Capsules in 50 mg, 100 mg, 200 mg, and 400 mg. Mylan stated that this product is the generic version of Celebrex® which is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and also for the management of acute pain in adults. According to the Company, under the terms of agreement, Mylan will begin selling the product at the earliest market formation, however in any case not later than December 2014. The full analyst notes on Mylan are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/MYL/report.pdf

--
Novartis AG (ADR) Analyst Notes
On June 1, 2014, Novartis AG (ADR) (Novartis) announced that Bruno Strigini has been appointed as President of Novartis Oncology, with effect on June 1, 2014. According to the Company, Mr. Strigini most recently served as President for Europe/Canada in Merck & Co, and has 25 years of experience leading both international and local roles in pharmaceuticals, animal health, OTC and vaccines. He also has a global perspective on the healthcare industry, and expertise across diverse geographies in both mature and emerging markets. The full analyst notes on Novartis are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/NVS/report.pdf

--
GlaxoSmithKline plc (ADR) Analyst Notes
On June 5, 2014, GlaxoSmithKline plc (ADR) (GSK) announced that it has commenced a pivotal phase III study, LATITUDE-TIMI 60, to evaluate the effects of losmapimod in patients with acute coronary syndrome. According to the Company, the phase III study will determine whether losmapimod can reduce the risk of a subsequent cardiac event when administered orally twice a day for three months, immediately after presentation of acute coronary syndrome. GSK stated that losmapimod is an inhibitor of p38 mitogen activated protein (MAP) kinase, which is an enzyme that plays a central role in the acute inflammation that occurs during a heart attack. Dr. John Lepore, Senior Vice President of Metabolic Pathways and Cardiovascular R&D at GSK said, "The start of our losmapimod study is an important step forward in the search for innovative therapies aimed at reducing the recurrence of cardiovascular events." The full analyst notes on GSK are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/GSK/report.pdf

--
Intercept Pharmaceuticals Inc Analyst Notes
On June 6, 2014, Intercept Pharmaceuticals Inc (Intercept) announced that its management will participate in upcoming investor conferences. According to the Company, CEO, Dr. Mark Pruzanski, will present at the Goldman Sachs 35th Annual Global Healthcare Conference on Thursday, June 12, 2014, at 10:40 a.m. PT, in Los Angeles, which will be followed by his participation at the City NASH Workshop on Monday, June 23, 2014, in New York. Additionally, Chief Strategy Officer, Dr. Rachel McMinn, will present at the JMP Securities Health Care Conference on Wednesday, June 25, 2014, at 10:00 a.m. ET, in New York. Intercept stated that live webcasts of each of the events will be posted on the Company's website under the Investors relation tab. Archived version of the webcasts will be available on Intercept's website for approximately two weeks after each event. The full analyst notes on Intercept are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/ICPT/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED